Ra Pharmaceuticals Inc (NASDAQ:RARX) insider Simon Read sold 10,000 shares of the stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $32.95, for a total value of $329,500.00. Following the transaction, the insider now owns 16,234 shares in the company, valued at $534,910.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Simon Read also recently made the following trade(s):

  • On Tuesday, June 18th, Simon Read sold 10,000 shares of Ra Pharmaceuticals stock. The stock was sold at an average price of $22.25, for a total value of $222,500.00.

Shares of NASDAQ RARX opened at $33.53 on Friday. The company has a market cap of $1.46 billion, a P/E ratio of -16.28 and a beta of 1.23. Ra Pharmaceuticals Inc has a 12-month low of $8.67 and a 12-month high of $34.50. The company has a current ratio of 20.10, a quick ratio of 20.10 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average of $27.07.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.02. Equities research analysts forecast that Ra Pharmaceuticals Inc will post -1.98 earnings per share for the current year.

A number of equities analysts have recently commented on the company. BidaskClub upgraded Misonix from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 3rd. Leerink Swann set a $5.00 target price on Tocagen and gave the stock a “hold” rating in a research report on Wednesday, May 22nd. SunTrust Banks lifted their target price on Wix.Com to $154.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. Zacks Investment Research lowered Hallmark Financial Services from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, ten have given a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $37.73.

Several hedge funds and other institutional investors have recently made changes to their positions in RARX. BlackRock Inc. lifted its position in shares of Ra Pharmaceuticals by 29.0% during the 4th quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock worth $48,142,000 after purchasing an additional 595,328 shares during the last quarter. Candriam Luxembourg S.C.A. grew its stake in shares of Ra Pharmaceuticals by 16.5% during the first quarter. Candriam Luxembourg S.C.A. now owns 1,024,000 shares of the company’s stock worth $22,939,000 after buying an additional 145,000 shares during the last quarter. FMR LLC grew its stake in shares of Ra Pharmaceuticals by 12.9% during the first quarter. FMR LLC now owns 466,834 shares of the company’s stock worth $10,457,000 after buying an additional 53,445 shares during the last quarter. Millennium Management LLC grew its stake in shares of Ra Pharmaceuticals by 407.0% during the fourth quarter. Millennium Management LLC now owns 412,066 shares of the company’s stock worth $7,500,000 after buying an additional 330,788 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Ra Pharmaceuticals by 3.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 406,120 shares of the company’s stock worth $7,391,000 after buying an additional 11,941 shares during the last quarter. 94.97% of the stock is currently owned by institutional investors and hedge funds.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: Correction

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.